A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma
| 适应症 | Melanoma |
|---|---|
| 分期 | 1/2期 |
| 申办方 | Jennerex Biotherapeutics |
| 状态 | 已完成 |
| 受试者人数 | 10 人 |
| 干预（药物） | JX-594 |
| 开始日期 | 2007年2月 |
| 完成日期 | 2008年2月 |
| 结果公布日 | 2026年7月27日 |
摘要
The purpose of this research study is to find out whether JX-594 (Pexa-Vec) is safe and effective for treating surgically unresectable malignant melanoma.
Number of Participants With Objective Response in Injected Tumor(s)
| Recombinant Vaccinia Virus JX-594 | 5 Participants with Stable disease |
|---|
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration — National Cancer Institute (NCI)
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-I — National Cancer Institute (NCI)
- Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab — National Cancer Institute (NCI)
- Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With — Bristol-Myers Squibb
- Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Select — National Cancer Institute (NCI)
- Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, — National Cancer Institute (NCI)